MYLENE: Patient and healthcare provider satisfaction with sc versus iv daratumumab administration in patients with newly diagnosed multiple myeloma in routine clinical practice in Germany.

15. Januar 2026

von der Heyde E.v.d.H., Reiser M., Baumgartner V., Englisch C., Frank O., Buchholz S., Kreimendahl F., Uhlig J., Bürkle D., Knauf W.

Oncol Res Treat 2025;48(suppl 2):208.